PAVmed (PAVM) Cash from Operations Growth (1y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -84.38% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 185.96% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 16.00% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.60% |
| 10 | PAVmed | 4.15 Mn | -9.02 Mn | -703,000.00 | -1,702.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,702.13% |
| Jun 30, 2025 | 89.70% |
| Mar 31, 2025 | 87.79% |
| Dec 31, 2024 | 100.79% |
| Jun 30, 2024 | 8.30% |
| Mar 31, 2024 | 19.88% |
| Dec 31, 2023 | 29.42% |
| Sep 30, 2023 | 42.67% |
| Jun 30, 2023 | 43.65% |
| Mar 31, 2023 | -33.43% |
| Dec 31, 2022 | -0.27% |
| Sep 30, 2022 | -141.22% |
| Jun 30, 2022 | -240.34% |
| Mar 31, 2022 | -33.76% |
| Dec 31, 2021 | -149.36% |
| Sep 30, 2021 | -37.29% |
| Jun 30, 2021 | -19.32% |
| Mar 31, 2021 | -141.84% |
| Dec 31, 2020 | -64.50% |
| Sep 30, 2020 | -102.92% |
| Jun 30, 2020 | -120.52% |
| Mar 31, 2020 | 2.04% |
| Dec 31, 2019 | -35.46% |
| Sep 30, 2019 | -54.19% |
| Jun 30, 2019 | -47.98% |
| Mar 31, 2019 | -75.92% |
| Dec 31, 2018 | -90.24% |
| Sep 30, 2018 | 21.33% |
| Jun 30, 2018 | -106.68% |
| Mar 31, 2018 | -20.54% |
| Dec 31, 2017 | -31.93% |
| Sep 30, 2017 | -93.38% |
| Jun 30, 2017 | 45.32% |
| Mar 31, 2017 | -251.87% |
| Dec 31, 2016 | -85.64% |
| Sep 30, 2016 | -286.07% |
| Jun 30, 2016 | -565.91% |
| Mar 31, 2016 | -800.66% |